Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

× No keyword cloud information.

142 in total

1. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors: Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal: Intern Emerg Med Date: 2015-11-24 Impact factor: 3.397

2. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors: Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal: United European Gastroenterol J Date: 2016-06-23 Impact factor: 4.623

Review 3. Probiotics and liver disease.

Authors: Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal: Perm J Date: 2013

4. Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.

Authors: Edoardo G Giannini; Claudia Coppo; Chiara Romana; Giovanni B Camerini; Franco De Cian; Nicola Scopinaro; Francesco S Papadia
Journal: Dig Dis Sci Date: 2018-04-09 Impact factor: 3.199

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

1. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

2. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Review 3. Probiotics and liver disease.

4. Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.

5. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Review 6. Clinical connection between rheumatoid arthritis and liver damage.

Review 7. NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Review 8. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Review 9. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

10. Assessment of fibrosis during the development of fatty liver in rabbits using real-time shear-wave elastography.